December 21, 2023
JCR Pharmaceuticals said on December 20 that the company and Takeda Pharmaceutical have agreed to terminate their collaboration to develop adeno-associated virus (AAV) gene therapies using its proprietary J-Brain Cargo blood-brain barrier (BBB) penetration technology. The move comes after Takeda’s...read more